J. K. Choksi
About
J. K. Choksi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, J. K. Choksi has authored 19 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in J. K. Choksi's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Cancer Treatment and Pharmacology (6 papers). J. K. Choksi is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (7 papers) and Cancer Treatment and Pharmacology (6 papers). J. K. Choksi collaborates with scholars based in United States and France. J. K. Choksi's co-authors include Gabriel N. Hortobágyi, Mohamed K. Ali, Sewa S. Legha, Robert S. Benjamin, Coleman K. Obasaju, Michael S. Ewer, Mark A. Socinski, Lowell L. Hart, Diane Prager and Charles Weissman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
J. K. Choksi
18 papers receiving 298 citations
Peers
J. K. Choksi
Wenliang Li China
Theodoros Marinakis Greece
Haocan Song United States
Richard Mansour United States
Vladimir Kovčin Serbia
Jake Jacob United States
Daniel Eiger Belgium
Rieko Minami Japan
Nazanin Aghel Canada
Simonetta Chiara Stani Italy
Citations per year, relative to J. K. Choksi J. K. Choksi (= 1×)
peers
Wenliang Li
Countries citing papers authored by J. K. Choksi
Since
Specialization
Citations
This map shows the geographic impact of J. K. Choksi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. K. Choksi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. K. Choksi more than expected).
Fields of papers citing papers by J. K. Choksi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J. K. Choksi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. K. Choksi. The network helps show where J. K. Choksi may publish in the future.
Co-authorship network of co-authors of J. K. Choksi
This figure shows the co-authorship network connecting the top 25 collaborators of J. K. Choksi. A scholar is included among the top collaborators of J. K. Choksi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. K. Choksi. J. K. Choksi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yardley, Denise A., James A. Reeves, Elizabeth Claire Dees, et al.. (2016). Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer. 16(6). 471–479.e1.
2.
Choy, Hak, Lee S. Schwartzberg, Shaker R. Dakhil, et al.. (2013). Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(10). 1308–1316.
3.
Choy, Hak, Lee S. Schwartzberg, Shaker R. Dakhil, et al.. (2012). Phase II study of pemetrexed (P) plus carboplatin (Cb) or cisplatin (C) with concurrent radiation therapy followed by pemetrexed consolidation in patients (pts) with favorable-prognosis inoperable stage IIIA/B non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). 7002–7002.
4.
Choy, H., Lee S. Schwartzberg, Shaker R. Dakhil, et al.. (2010). Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update.. Journal of Clinical Oncology. 28(15_suppl). 7082–7082.
5.
Socinski, Mark A., Robert N. Raju, Thomas E. Stinchcombe, et al.. (2010). Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(12). 1963–1969.
6.
Stinchcombe, Thomas E., et al.. (2008). Preliminary safety and efficacy data of a phase II trial of vinflunine and cetuximab in the second-line treatment of patients with advanced non-small cell lung cancer. Journal of Clinical Oncology. 26(15_suppl). 19100–19100.
7.
Lesser, Glenn J., Douglas Case, Faith D. Ottery, et al.. (2008). A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 9513–9513.
8.
Ansari, Rafat, Mark A. Socinski, J. K. Choksi, et al.. (2008). A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab followed by bevacizumab alone in patients with locally advanced or metastatic non-small cell lung cancer (central localization excluded). Journal of Clinical Oncology. 26(15_suppl). 19077–19077.
9.
Noga, Stephen J., J. K. Choksi, Beiying Ding, Lyndah Dreiling, & Howard Ozer. (2007). Low Incidence of Neutropenic Events in Patients with Lymphoma Receiving First-Cycle Pegfilgrastim with Chemotherapy: Results from a Prospective Community-Based Study. Clinical Lymphoma & Myeloma. 7(6). 413–420.
10.
Stinchcombe, Thomas E., Petra Bůžková, J. K. Choksi, et al.. (2006). A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer. 52(3). 305–311.
11.
Noga, Stephen J., J. K. Choksi, Beiying Ding, Lyndah Dreiling, & Howard Ozer. (2006). Final Results of a Large, Community Based Study Evaluating the Impact of First and Subsequent Cycle Pegfilgrastim on Neutropenic Events in NHL and HD Patients.. Blood. 108(11). 1153–1153.
12.
Socinski, Mark A., Charles Weissman, Lowell L. Hart, et al.. (2006). Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(30). 4840–4847.
13.
Lesser, Glenn J., Douglas Case, Sarah Sharp, et al.. (2006). A Phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology. 24(18_suppl). 18546–18546.
14.
Stinchcombe, Thomas E., Mark A. Socinski, J. K. Choksi, et al.. (2005). A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7259–7259.
15.
Stinchcombe, Thomas E., Mark A. Socinski, J. K. Choksi, et al.. (2005). P-576 A phase I/II trial of weekly docetaxel and gefitinib in elderlypatients (⩾70) with stage IIIB/IV non-small cell lung cancer (NSCLC). Lung Cancer. 49. S270–S270.
16.
Socinski, Mark A., Lowell L. Hart, J. Thaddeus Beck, et al.. (2005). A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology. 23(16_suppl). 7165–7165.
17.
Socinski, Mark A., Charles Weissman, Lowell L. Hart, et al.. (2004). Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer. Journal of Clinical Oncology. 22(14_suppl). 7204–7204.
18.
Socinski, Mark A., Charles Weissman, Lowell L. Hart, et al.. (2004). Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer. Journal of Clinical Oncology. 22(14_suppl). 7204–7204.
19.
Legha, Sewa S., J. K. Choksi, Gabriel N. Hortobágyi, et al.. (1985). Doxorubicin-induced congestive heart failure in adults. Cancer. 56(6). 1361–1365.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Wenliang Li Breakdown of academic impact, for papers by Theodoros Marinakis Breakdown of academic impact, for papers by Haocan Song Breakdown of academic impact, for papers by Richard Mansour Breakdown of academic impact, for papers by Vladimir Kovčin Breakdown of academic impact, for papers by Jake Jacob Breakdown of academic impact, for papers by Daniel Eiger Breakdown of academic impact, for papers by Rieko Minami Breakdown of academic impact, for papers by Nazanin Aghel Breakdown of academic impact, for papers by Simonetta Chiara Stani